Abstract
We herein describe a rare case of adult acute lymphoblastic leukemia with an 18florine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) skeletal superscan-like appearance. The degree of bone marrow uptake was so intense that it far exceeded the level of physiological cerebral uptake and radiourinary activity. The distribution was remarkably similar to a superscan seen on skeletal scintigraphy. Skeletal superscans of 18F-FDG PET/CT have been reported in hematological diseases, solid tumors with extensive bone metastasis, and metabolic diseases. Thus, we reviewed the PET/CT images of cases reported, indicating that more homogeneous distribution, without primary tumor and specific mandibular and skull activity, may be suggestive of hematological diseases.
Introduction
Acute lymphoblastic leukemia (ALL) is one of the predominant subtypes of leukemia characterized (). It is the most common malignancy in childhood with a typical age of presentation between 1 and 4 years and is rarely seen in adults (). Clinical presentation can be nonspecific and span a spectrum of symptoms and signs. The majority of patients present with fever, pallor, and bruising as early signs of marrow suppression or hematologic abnormalities (). It is difficult to accurately diagnose ALL using conventional imaging techniques (). The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have demonstrated the application value of positron emission tomography/computed tomography (PET/CT) in ALL (). Some ALL can present with intense bone marrow uptake on an 18florine-fluorodeoxyglucose (18F-FDG) PET/CT skeletal superscan-like image, although superscans have been described in both benign and malignant diseases (). In this case report, we present the unusual 18F-FDG PET/CT scan performance of a patient with ALL and review the relevant literature on this subject.
Case presentation
A 74-year-old male patient with a two-week history of fever, generalized weakness, and shortness of breath. The patient was a nonsmoker with no history of high blood pressure, diabetes, heart disease, familial inheritance, or malignancy. Laboratory examinations revealed decreased hemoglobin with 36g/L (normal range, 120-160 g/L), leukopenia (3.32 x 109/L; normal range, 4-10 x 109/L), thrombopenia (22 x 109/L; normal range, 100-300 x 109/L), total protein (48.61g/L; normal range, 63-85 g/L), albuminopenia (25.32g/L, normal range, 40-55 g/L), and A/G (1.09; normal range, 1.5-2.5). Furthermore, serum ferritin (2585ng/ml; normal range, 30-400 ng/ml), lactate dehydrogenase (570U/L: normal range, 0-248 U/L), urea (10.8 mmol/L; normal range, 2.86-7.14 mmol/L), crea (119 umol/L; normal range, 45-84 umol/L), and c-reactive protein (176.99mg/L; normal range, 0-10 mg/L) increased. The patient’s performance status (PS) score was 3. CT showed lung infection, irregular liver margins, and a markedly enlarged spleen. The patient received blood transfusions without cytokine release therapy or drug interference that could disturb bone marrow glucose metabolisms. The patient underwent an 18F-FDG PET/CT scan (Figure 1) and bone marrow biopsy for further diagnosis. Interestingly, the 18F-FDG PET/CT scan showed markedly increased diffuse uptake in axial and appendicular bone marrow with a maximum standardized uptake value (SUVmax) of 14.5 and also in the liver and spleen with a SUVmax 9.4 and 12.3, respectively. Furthermore, the brain (SUVmax 1.3), muscles (SUVmax 0.7), kidney (SUVmax 3.3), and bladder (SUVmax 3.2) were barely discernible as background activity. Axial sections of fused PET/CT images showed increased FDG uptake in slightly enlarged lymph nodes in the retroperitoneal and bilateral inguinal areas. The findings from the 18F-FDG PET/CT scan showed increased skeletal radiotracer uptake relative to soft tissues and absent or faint genitourinary tract activity suggestive of a superscan-like pattern. The results of bone marrow cytology 1 day later suggested ALL, which was consistent with the 18F-FDG PET/CT findings, although these were not specific and challenging in the initial diagnosis. Histopathology of the liver and spleen was not performed due to the patient’s poor basal status. After 7 days of hospitalization, the patient refused further tests and treatment and requested to be discharged. Unfortunately, his condition rapidly worsened and he expired within 1 day.
Figure 1
Discussion
Acute leukemia (AL) has become a global health concern due to its increasing incidence over the past decade. Acute lymphoblastic leukemia is one of the most studied leukemias. It is characterized by a proliferation of lymphoid precursor cells in the bone marrow and other extramedullary sites. Diagnosing leukemia and assessing its potential spread to sites outside the bone marrow at early stages is essential for adequate management and mitigation of the complications. In recent years, more research reports have shown that 18F-FDG PET/CT also plays an important role in the diagnosis and treatment of ALL (, ).
In our patient, on an 18F-FDG PET scan, intense and homogeneous radiotracer uptake was observed in the axial and appendicular skeleton, and background activity in the genitourinary system, brain, and soft tissues was barely visible. The distribution of 18F-FDG showed a “superscan-like” appearance that was remarkably similar to that on the skeletal scintigraphy, showing an interesting phenomenon. The brain uptake is reportedly decreased in patients with extensive lymphoma lesions with the SUVmax of the brains of patients and controls was 13.1 ± 2.3 vs 14.9 ± 2.4 (). In this case, the patient’s brain had very low activity with a SUVmax of 1.3, which is quite rare in the daily clinical practice.
The term “super bone scan” or “superscan” was first proposed by Osmond et al. in 1975, which was originally described as the appearance of the skeleton standing out “in bold relief” with faint radiotracer in the soft tissues and kidneys in a pattern on 99mTc-methylene diphosphonate skeletal scintigraphy (). Later, Su et al. generalized the application of this term to similar features found in PET/CT (). This feature “looks too good” due to the diffuse and symmetric skeletal uptake, similar to the appearance of a bone scan. To date, diffuse tracer uptake in the skeleton/bone marrow as a skeletal superscan pattern on 18F-FDG PET/CT has been previously reported in hematological diseases (including two cases of multiple myeloma (, ), two cases of lymphoma and two cases of acute lymphoblastic leukemia (, –), and one case of hemophagocytic lymphohistiocytosis) (), nine cases of solid tumors with extensive bone metastasis (, –), and metabolic diseases with three cases of hyperparathyroidism and one case of renal osteodystrophy (–). By reviewing all the medical images of the reports, the hematological diseases revealed greater homogeneous radiotracer uptake in the skeleton, as in our case, and the metabolic diseases all had a specific skull and mandible intense uptake pattern. Thus, highly homogeneous radiotracer uptake in the skeleton without skull and mandible intense uptake and a primary tumor indicate hematological diseases, although it is difficult to determine the subtype.
In leukemia, 18F-FDG PET/CT is of use in diagnosing, staging, restaging, assessing extramedullary involvement, follow-up, and detecting Richter transformation (). It is used especially in those people with nonspecific symptoms, such as fever and anemia of unknown origin, for detecting and monitoring extramedullary and unusual relapse sites and evaluating treatment response (–). It also plays an important role in the early detection of Richter’s syndrome (RS) and guiding biopsy in chronic lymphoblastic leukemia (CLL). Furthermore, it can also be used to diagnose graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (). We found two case reports that reported patients with fever of unknown origin, and while examination of their peripheral blood showed no remarkable abnormalities, PET/CT revealed diffuse high 18F-FDG uptake in the bone marrow, suggesting the diagnosis of ALL (, ). In our case, the patient had a fever of unknown origin for two weeks, and the PET/CT scan indicated bone marrow abnormality without solid tumor uptake, which was suggestive of possible hematological disease.
In ALL, increased uptake of 18F-FDG in bone marrow may be a characteristic finding, including diffuse and focal patterns. However, increased bone marrow 18F-FDG uptake can also be observed in benign etiologies and other types of malignant infiltration, including following administration of growth factors, such as colony-stimulating growth factor or erythropoietin (). Thus, it is difficult to differentiate. Some articles have reported that bone marrow malignant infiltration derived from lymphoma and leukemia generally has a markedly higher 18F-FDG uptake in the bone marrow compared with benign etiologies (, ).
Some studies focused on the prognostic value of PET/CT findings. Zhao et al. analyzed a total of 72 patients with acute leukemia and found that the presence of extranodal, extramedullary, and extrasplenic sites was identified as an independent prognostic indicator when treated with allogeneic hematopoietic stem cell transplantation treatment (). The patient in our case died very soon. In the reported case of two ALL patients with superscan, one was reported dead two months after the PET/CT scan, suggestive of a considerably poor prognosis (), while the outcome for the other was not reported. However, the sample was too small. The prognostic value of PET/CT remains to be explored.
In summary, the initial clinical presentation of ALL is variable and 18F FDG PET/CT is helpful in diagnoses, especially in those with a fever of unknown origin. The skeletal superscan-like appearance of 18F-FDG PET/CT is a rare phenomenon in clinical practice. It has been reported in hematological diseases, solid tumors, and metabolic diseases and the specific imaging patterns may help us to find the cause of illness.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
YH: Data curation, Writing – original draft, Writing – review & editing. WD: Resources, Writing – review & editing. PW: Resources, Writing – review & editing. YF: Data curation, Writing – review & editing. HF: Supervision, Writing – review & editing. JL: Supervision, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
DeAngeloDJJabbourEAdvaniA. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. (2020) 40:330–42. doi: 10.1200/EDBK_280175
2
MedingerMHeimDLengerkeCHalterJPPasswegJR. Acute lymphoblastic leukemia - diagnosis and therapy. Ther Umsch. (2019) 76:510–5. doi: 10.1024/0040-5930/a001127
3
ChangJHPoppeMMHuaCHMarcusKJEsiashviliN. Acute lymphoblastic leukemia. Pediatr Blood Cancer. (2021) 68 Suppl 2:e28371. doi: 10.1002/pbc.28371
4
ArberDAOraziAHasserjianRThieleJBorowitzMJLe BeauMMet al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. (2016) 127:2391–405. doi: 10.1182/blood-2016-03-643544
5
BrownPAShahBAdvaniAAounPBoyerMWBurkePWet al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. (2021) 19:1079–109. doi: 10.6004/jnccn.2021.0042
6
ParidaGKSoundararajanRPassahABalCKumarR. Metabolic skeletal superscan on 18F-FDG PET/CT in a case of acute lymphoblastic leukemia. Clin Nucl Med. (2015) 40:567–8. doi: 10.1097/RLU.0000000000000785
7
Al-IbraheemAAllouziSAbdlkadirASMikhail-LetteMAl-RabiKMa'kosehMet al. PET/CT in leukemia: utility and future directions. Nucl Med Commun. (2024) 45:550–63. doi: 10.1097/MNM.0000000000001846
8
ZhaoZHuYLiJZhouYZhangBDengS. Applications of PET in diagnosis and prognosis of leukemia. Technol Cancer Res Treat. (2020) 19:1533033820956993. doi: 10.1177/1533033820956993
9
OtomiYOtsukaHShonoNOnishiHMitsuhashiRMatsuzakiSet al. A reduced physiological (18)F-fluorodeoxyglucose uptake in the brain and liver caused by Malignant lymphoma being deprived of the tracer. J Med Invest. (2021) 68:181–5. doi: 10.2152/jmi.68.181
10
HongHPloesslKZhaZWangHGuoRXieQet al. Development and validation of a kit formulation of [(68)Ga]Ga-P15-041 as a bone imaging agent. Appl Radiat Isot. (2021) 169:109485. doi: 10.1016/j.apradiso.2020.109485
11
SuHYLiuRSLiaoSQWangSJ. F-18 FDG PET superscan. Clin Nucl Med. (2006) 31:28–9. doi: 10.1097/01.rlu.0000191569.37542.3d
12
FuZChenXYangXLiQ. Skeletal superscan on 18F-FDG PET/CT in a patient with multiple myeloma. Clin Nucl Med. (2019) 44:169–70. doi: 10.1097/RLU.0000000000002404
13
AnCZhaiLGengHWangPZhangW. 18F-FDG PET/CT findings in a patient with neutrophilic leukemoid reaction associated with multiple myeloma. Clin Nucl Med. (2020) 45:405–6. doi: 10.1097/RLU.0000000000002999
14
Acevedo-BáñezIDe-Bonilla-DamiáÁFernández-LópezR. (18)F-FDG PET/CT «superscan» in a patient with immunoblastic lymphoma. Rev Esp Med Nucl Imagen Mol (Engl Ed). (2019) 38:252–3. doi: 10.1016/j.remn.2018.04.004
15
KoçZPÖzcan KaraPAkdenizAYaldızM. Lymphoblastic involvement of the bone marrow as a cause of superscan appearance in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Mol Imaging Radionucl Ther. (2020) 29:85–7. doi: 10.4274/mirt.galenos.2019.42104
16
Yousefi-KomaAShiravandYQutbiM. Diffuse skeletal uptake on (18)F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan in a patient with acute lymphoblastic leukemia: A typical superscan pattern resembling naF positron emission tomography scan. Indian J Nucl Med. (2019) 34:326–8. doi: 10.4103/ijnm.IJNM_106_19
17
LawWPEmmettSJacksonP. 18F-FDG superscan caused by extensive bone marrow involvement in hemophagocytic lymphohistiocytosis. Clin Nucl Med. (2017) 42:617–9. doi: 10.1097/RLU.0000000000001699
18
MuzaffarMHassanA. "Superscan" on F18-fluorodeoxyglucose positron emission tomography - computed tomography [18-F] FDG PET-CT. J Pak Med Assoc. (2021) 71:1907–8.
19
KimDWKimCGParkSAJungSAYangSH. Metabolic super scan in F-FDG PET/CT imaging. J Korean Med Sci. (2010) 25:1256–7. doi: 10.3346/jkms.2010.25.8.1256
20
ChengGAlaviALimEAkersSR. Superscan-like hypermetabolic lesions on delayed FDG PET/CT imaging in a patient with lung cancer. Clin Nucl Med. (2012) 37:912–3. doi: 10.1097/RLU.0b013e31825b23d5
21
BaillyMBesseHKerdraonRMetrardGGauvainS. 18F-FDG PET/CT superscan in prostate cancer. Clin Nucl Med. (2014) 39:912–4. doi: 10.1097/RLU.0000000000000376
22
ChanMSchembriGP. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in metastatic pancreatic neuroendocrine tumor. Clin Nucl Med. (2017) 42:108–9. doi: 10.1097/RLU.0000000000001499
23
FujiiMKiuraKTakigawaNTakedaHTanimotoM. Super scan using positron emission tomography in lung cancer patients. J Thorac Oncol. (2007) 2:1042–3. doi: 10.1097/JTO.0b013e318158ef15
24
YamaneHOchiNHondaYTakigawaN. PET superscan caused by lung cancer. Intern Med. (2015) 54:2951. doi: 10.2169/internalmedicine.54.5211
25
MalhotraGSwamiAShahPMittalNGandhiSJTiwariBet al. F-18 fluorodeoxyglucose positron emission tomography "super scan" in a patient of metastatic primitive neuroectodermal tumor of the kidney. Indian J Nucl Med. (2012) 27:115–8. doi: 10.4103/0972-3919.110709
26
Mohd RohaniMFBujangNLRosdiAHAmir HassanSZ. Metabolic superscan on 18 F-FDG PET/CT in a patient with secondary hyperparathyroidism. Clin Nucl Med. (2024) 49:e19–21. doi: 10.1097/RLU.0000000000004941
27
GrellierJFLussatoDQueneauMGuernouMSongyB. Secondary hyperparathyroidism with "Superscan-like" Hypermetabolic FDG PET/CT pattern. Clin Nucl Med. (2015) 40:888–9. doi: 10.1097/RLU.0000000000000952
28
SampathSJeevaG. Parathyroid carcinoma - A Malignant cause of metabolic skeletal super scan on fluorodeoxyglucose positron emission tomography-computed tomography. Indian J Nucl Med. (2021) 36:223–5. doi: 10.4103/ijnm.ijnm_213_20
29
LawalIAnkrahAOloladeKModiselleMSathekgeM. Renal osteodystrophy presenting as a metabolic superscan on F-18 FDG PET/CT: A case report. Med (Baltimore). (2017) 96:e8471. doi: 10.1097/MD.0000000000008471
30
SalemAEShahHRCovingtonMFKoppulaBRFineGCWigginsRH. PET-CT in clinical adult oncology: I. Hematologic Malignancies. Cancers (Basel). (2022) 14:5941. doi: 10.3390/cancers14235941
31
ArslanFYilmazMCakirTMertA. Significant contribution of Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in a case of acute lymphoblastic leukemia presenting with fever of unknown origin. Intern Med. (2014) 53:789–91. doi: 10.2169/internalmedicine.53.1443
32
KuniedaHDendaRYamazakiKHiraoMTsukadaYIwabuchiYet al. Philadelphia chromosome-positive acute lymphoblastic leukemia incidentally detected by fluorodeoxyglucose-positron emission tomography/computed tomography at a health checkup. Intern Med. (2022) 61:2775–8. doi: 10.2169/internalmedicine.8900-21
33
EndoTSatoNKoizumiKNishioMFujimotoKSakaiTet al. Localized relapse in bone marrow of extremities after allogeneic stem cell transplantation for acute lymphoblastic leukemia. Am J Hematol. (2004) 76:279–82. doi: 10.1002/ajh.20106
34
AlamMSFuLRenYYWuHBWangQSHanYJet al. 18F-FDG super bone marrow uptake: A highly potent indicator for the Malignant infiltration. Med (Baltimore). (2016) 95:e5579. doi: 10.1097/MD.0000000000005579
35
ZhouMChenYLiuJHuangG. A predicting model of bone marrow Malignant infiltration in (18)F-FDG PET/CT images with increased diffuse bone marrow FDG uptake. J Cancer. (2018) 9:1737–44. doi: 10.7150/jca.24836
36
ZhaoZZhouYWangJZhangTLiJZhangBet al. The value of (18)F-FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation. Oncol Lett. (2020) 20:175. doi: 10.3892/ol
Summary
Keywords
acute lymphoblastic leukemia, 18F-FDG PET/CT, bone marrow, diffuse uptake, superscan
Citation
Hu Y, Dai W, Wang P, Feng Y, Feng H and Li J (2024) Case report: 18F-FDG PET/CT skeletal superscan-like in an adult patient with acute lymphoblastic leukemia. Front. Oncol. 14:1401453. doi: 10.3389/fonc.2024.1401453
Received
15 March 2024
Accepted
26 June 2024
Published
15 July 2024
Volume
14 - 2024
Edited by
Mohamed A. Yassin, Qatar University, Qatar
Reviewed by
Akram Al-ibraheem, King Hussein Cancer Center, Jordan
Domenico Albano, University of Brescia, Italy
Updates
Copyright
© 2024 Hu, Dai, Wang, Feng, Feng and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wenli Dai, daiwenli@ctgu.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.